Funds led by Carlyle have acquired a majority stake in Saama Technologies, according to a news release.
The investment is valued at up to $430 million.
Saama, based in Campbell, Calif., is an AI clinical analytics platform company. Founded in 1997, the company states that biotech companies use Saama’s Life Science Analytics Cloud platform to support more than 1,500 studies.
Carlyle, with its U.S. headquarters in Washington, D.C., is a global investment firm that deploys private capital across three business segments: global private equity, global credit and investment solutions. Founded in 1987, the firm targets companies in healthcare and many other industries.
Co-investors joining Carlyle in the investment included Amgen Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, McKesson Ventures, Northpond Ventures, Pfizer Ventures and Population Health Partners.
